Fangzhou Inc. and Tencent Healthcare unveil AI-powered chronic disease management platform

Fangzhou Inc. and Tencent Healthcare have jointly introduced an AI-driven chronic disease management platform in China, designed to support hospitals and industry partners with an end-to-end technology pipeline. The system covers model training, scenario testing and deployment, and is intended to improve the efficiency and intelligence of long-term condition management.

The platform is built on Fangzhou’s AI+H2H (Hospital-to-Home) framework, which integrates the company’s proprietary large-model capabilities into clinical and at-home care workflows. Tencent Cloud contributes cloud computing, big data and AI infrastructure to underpin the technical performance of the solution.

Safety and compliance form a core part of the development. Fangzhou has introduced several mechanisms to reduce the risk of hallucinations in clinical use, including reinforcement learning with curated medical knowledge, rule-based oversight and additional checks to align outputs with medical scenarios.

The underlying model is supported by Tencent Healthcare’s TI platform, which provides unified training, evaluation and deployment processes to enable continuous optimisation. Tencent Healthcare’s vector database—designed to store large volumes of medical knowledge—offers millisecond-level semantic retrieval to strengthen the accuracy of retrieval-augmented generation outputs. Its AI security WAF adds threat detection and encrypted protection for sensitive healthcare data to support regulatory compliance.

The collaboration is aligned with recent guidance from the National Health Commission on the safe and standardised application of AI in healthcare. Both companies said the joint solution is intended to support the digital transformation of chronic care and contribute to national health goals under the “Healthy China 2030” initiative.

The launch follows a period of growth for Fangzhou’s AI services. The company’s “medical report interpretation” feature, released in October, has seen strong uptake, reflecting patient demand for clearer explanations of laboratory results and increasing confidence in AI-enabled healthcare tools.